40例消化系统神经内分泌癌的临床分析

Neuroendocrine carcinoma in digestive system: A clinical analysis of 40 patients

  • 摘要: 目的 提高对消化系统神经内分泌癌的诊治水平。 方法 回顾我科1998年1月-2011年12月消化系统神经内分泌癌40例患者的病例资料并进行随访,分析消化系统神经内分泌癌发病部位、临床特点、疗效及预后。 结果 发病部位以食管、胃为主(14例和9例);病理分型以小细胞癌为主(50%);26例接受了依托泊苷联合顺铂或卡铂为主的一线治疗方案,有效率23.1%,疾病控制率69.2%,以食管、胃和肠道部位的患者治疗效果较好;而胰腺、肝脏和腹腔部位疗效较差;20例接受了二线化疗,均为伊立替康联合氟尿嘧啶为主的化疗方案,有效率15%,疾病控制率65%。存活6例,最长为47个月,中位生存时间15个月。 结论 消化系统神经内分泌癌以食管、胃多见,部分病例对化疗敏感,但缓解期短,总体生存期较短。

     

    Abstract: Objective To analyze the location, clinical characteristics, curative effect and prognosis of neuroendocrine carcinoma(NEC) in the digestive system. Methods Clinical data about 40 patients with NEC in the digestive system admitted to our hospital from January 1998 to December 2011 were retrospectively analyzed.The patients were followed up. Results NEC was located in esophagus of 14 patients and in stomach of 9 patients.Histological typing showed that 50% of the NEC was found to be small cell cancer.Twenty-six patients were treated with etoposide and cisplatin/carboplatin as the first line chemotherapy, with an effective rate of 23.1% and a disease control rate of 69.2%.The therapeutic effect was good for esophageal, gastric and intestinal NEC, whereas poor for pancreatic, hepatic and abdominal NEC.Twenty patients underwent combined irinotecan and fluorouracil treatment as the second line chemotherapy with an effective rate of 15% and a disease control rate of 65%.Of these 20 patients, 6 survived with a longest survival time of 47 months (mean 15 months). Conclusion NEC is frequently found in esophagus and stomach.Some NEC patients are sensitive to chemotherapy, but their remission and overall survival time are short.

     

/

返回文章
返回